Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, et al
I didnt take a GLP-1 to become thin or fit into a narrower mold of what an athlete looks like: hell, Im still considered obese by all measures
Similarly, in another ex vivo study by Aroon and colleagues, empagliflozin suppressed advanced glycation end products, restored eNOS activation and reduced interstitial and periarterial NO stress ( Nevertheless, volume depletion and hemoconcentration induced by SGLT-2i raised the question about a possible pro-thrombotic effect
Early data from Alzheimer's trials has generated genuine excitement, proposing that GLP-1 signaling may modulate the neuroinflammation that drives cognitive decline
One particularly notable case report described a 23-year-old female who developed alopecia areata, an autoimmune form of hair loss, just two months after starting semaglutide
The authors are available to speak on topics including: The benefits and risks of GLP-1 drugs for weight loss Emerging uses including heart and kidney disease, sleep apnea, osteoarthritis, Alzheimers, Parkinsons and addiction Questions about long-term safety (e.g